nach oben

Erschienen in:

01.01.2010 | Melanomas

Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients

verfasst von: Robert Howman-Giles, MD, FRACP, DDU, Helen M. Shaw, PhD, Richard A. Scolyer, MD, FRCPA, FRCPath, Rajmohan Murali, MBBS, FRCPA, James Wilmott, BSc, Stanley W. McCarthy, MB, BS, DCP, FRCPA, FFOP, Roger F. Uren, MD, FRACP, DDU, John F. Thompson, MD, FRACS, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The rarity of melanoma in young patients, particularly pediatric ones, has to date precluded any valid comparisons being made between young patients and adults undergoing sentinel lymph node biopsy (SLNB) for intermediate thickness localized melanoma. The present study takes advantage of the large Sydney Melanoma Unit (SMU) database to clarify this issue.

Materials and Methods

Clinical and pathologic data on pediatric and adolescent AJCC Stage I and II cutaneous melanoma patients aged <20 years undergoing SLNB at the SMU between January 1993 and February 2008 were reviewed. SLNB positivity rates and outcomes in these patients were compared with adult SMU patients.

Results

In 55 young patients, overall median tumor thickness was 1.7 mm (range, 0.6–5.2 mm) and overall SLNB positivity rate was 14 of 55 (25%), tumors tending to be thicker (median, 2.6 mm), and SLNB positivity rate higher (2 of 6; 33%) in patients aged <10 years. Of the 14 patients, 13 underwent immediate completion lymph node dissection (CLND); 2 patients had non-SLN metastases (15.4%). Only 0.7% of a total of 295 lymph nodes removed at CLND were involved with melanoma. In 14 SLNB-positive patients with follow-up data, 3 (21%) have died from melanoma after a median follow-up of 60 months, compared with 42% of 356 SLNB positive adults.

Conclusions

Although the SLNB positivity rate was higher in pediatric and adolescent melanoma patients than in adults (25% vs. 17%, respectively), non-SLN positivity and melanoma-specific death rates were low.

Conti EM, Cercato MC, Gatta G, Ramazzotti V, Roscioni S, EUROCARE Working Group. Childhood melanoma in Europe since 1978: a population-based survival study. Eur J Cancer. 2001;37:780–4.CrossRefPubMed

Downard CD, Rapkin LB, Gow KW. Melanoma in children and adolescents. Surg Oncol. 2007;16:215–20.CrossRefPubMed

Hamre MR, Chuba P, Bakhshi S, Thomas R, Severson RK. Cutaneous melanoma in childhood and adolescence. Pediatr Hematol Oncol. 2002;19:309–17.CrossRefPubMed

Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007;25:1363–8.CrossRefPubMed

Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39:2651–61.CrossRefPubMed

Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23:4735–41.CrossRefPubMed

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.PubMed

Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302–11 (discussion 311–3).PubMed

Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.CrossRefPubMed

10.

Caraco C, Marone U, Botti G, Celentano E, Lastoria S, Mozzillo N. Age as predictor in patients with cutaneous melanoma submitted to sentinel lymph node biopsy. Eur J Surg Oncol. 2006;32:970–3.CrossRefPubMed

11.

Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, van Diest PJ, Pijpers R, Ferwerda CC, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer. 2001;91:2401–8.CrossRefPubMed

12.

Ferrari A, Bono A, Baldi M, Collini P, Casanova M, Pennacchioli E, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics. 2005;115:649–54.CrossRefPubMed

13.

Livestro DP, Kaine EM, Michaelson JS, Mihm MC, Haluska FG, Muzikansky A, et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer. 2007;110:614–24.CrossRefPubMed

14.

Roaten JB, Partrick DA, Pearlman N, Gonzalez RJ, Gonzalez R, McCarter MD. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005;40:232–5.CrossRefPubMed

15.

Kogut KA, Fleming M, Pappo AS, Schropp KP. Sentinel lymph node biopsy for melanoma in young children. J Pediatr Surg. 2000;35:965–6.CrossRefPubMed

16.

Neville HL, Andrassy RJ, Lally KP, Corpron C, Ross MI. Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg. 2000;35:961–4.CrossRefPubMed

17.

Toro J, Ranieri JM, Havlik RJ, Coleman JJ III, Wagner JD. Sentinel lymph node biopsy in children and adolescents with malignant melanoma. J Pediatr Surg. 2003;38:1063–5.CrossRefPubMed

18.

Thompson JF. Operative technique for sentinel lymphadenectomy: blue dye identification and use of a gamma probe. In: Nieweg OE, Essner R, Reintgen D, Thompson JF, editors. Lymphatic mapping and probe applications in oncology. New York: Marcel Dekker; 2000. p. 71–86.

19.

Thompson JF, Niewind P, Uren RF, Bosch CM, Howman-Giles R, Vrouenraets BC. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res. 1997;7:500–6.CrossRefPubMed

20.

Thompson JF, Shaw HM. Sentinel node mapping for melanoma: results of trials and current applications. Surg Oncol Clin N Am. 2007;16:35–54.CrossRefPubMed

21.

Uren RF, Howman-Giles R, Thompson JF, Shaw HM, Quinn MJ, O’Brien CJ, et al. Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Res. 1994;4:395–9.CrossRefPubMed

22.

Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med. 1993;34:1435–40.PubMed

23.

Li LX, Scolyer RA, Ka VS, McKinnon JG, Shaw HM, McCarthy SW, et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Pathol. 2003;27:1197–202.CrossRefPubMed

24.

Scolyer RA, McCarthy SW, Elder DE. Frontiers in melanocytic pathology. Pathology. 2004;36:385–6.CrossRefPubMed

25.

Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol. 2008;25:100–11.CrossRefPubMed

26.

Thompson JF, Shaw HM. The surgical management of cutaneous melanoma: have we made any real progress in 100 years? Cancer Forum. 2006;30:103–6.

27.

(AACR) AIoHaWAAAoCR. Cancer in Australia 2001. Vol. AIHW cat. no. CAN 23. Canberra: Australian Institute of Health and Welfare; 2004.

28.

Shaw HM, Thompson JF. Cutaneous melanoma in childhood: incidence and prognosis. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of melanoma. London: Martin Dunitz; 2004. p. 379–86.

29.

Sassen S, Shaw HM, Colman MH, Scolyer RA, Thompson JF. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center. Ann Surg Oncol. 2008;15:630–7.CrossRefPubMed

30.

Gibbs P, Moore A, Robinson W, Walsh P, Golitz L, Gonzalez R. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol. 2000;22:428–32.CrossRefPubMed

31.

Chao C, Martin RC II, Ross MI, Reintgen DS, Edwards MJ, Noyes RD, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11:259–64.CrossRefPubMed

32.

Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, Grover AC, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247–58.CrossRefPubMed

33.

Pacella SJ, Lowe L, Bradford C, Marcus BC, Johnson T, Rees R. The utility of sentinel lymph node biopsy in head and neck melanoma in the pediatric population. Plast Reconstr Surg. 2003;112:1257–65.CrossRefPubMed

34.

Shah NC, Gerstle JT, Stuart M, Winter C, Pappo A. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. J Pediatr Hematol Oncol. 2006;28:496–500.CrossRefPubMed

35.

Topar G, Zelger B. Assessment of value of the sentinel lymph node biopsy in melanoma in children and adolescents and applicability of subcutaneous infusion anesthesia. J Pediatr Surg. 2007;42:1716–20.CrossRefPubMed

36.

Pan WR, Suami H, Taylor GI. Senile changes in human lymph nodes. Lymphat Res Biol. 2008;6:77–83.CrossRefPubMed

37.

Crotty KA, Scolyer RA, Li L, Palmer AA, Wang L, McCarthy SW. Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished? Pathology. 2002;34:6–12.CrossRefPubMed

38.

Dahlstrom JE, Scolyer RA, Thompson JF, Jain S. Spitz naevus: diagnostic problems and their management implications. Pathology. 2004; 36:452–7.CrossRefPubMed

39.

McCarthy SW, Scolyer RA. Melanocytic lesions of the face: diagnostic pitfalls. Ann Acad Med Singap. 2004;33:3–14.PubMed

40.

Scolyer R, Thompson J, Stretch JR, McCarthy SW. Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients. Cancer Forum. 2005;29:76–81.

41.

Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology. 2004;36:428–34.CrossRefPubMed

42.

Barnhill RL, Argenyi ZB, From L, Glass LF, Maize JC, Mihm MC Jr, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30:513–20.CrossRefPubMed

43.

Cerroni L, Kerl H. Tutorial on melanocytic lesions. Am J Dermatopathol. 2001;23:237–41.CrossRefPubMed

44.

Mones JM, Ackerman AB. “Atypical” Spitz’s nevus, “malignant” Spitz’s nevus, and “metastasizing” Spitz’s nevus: a critique in historical perspective of three concepts flawed fatally. Am J Dermatopathol. 2004;26:310–33.CrossRefPubMed

45.

Spatz A, Barnhill RL. The Spitz tumor 50 years later: revisiting a landmark contribution and unresolved controversy. J Am Acad Dermatol. 1999;40:223–8.CrossRefPubMed

46.

Gamblin TC, Edington H, Kirkwood JM, Rao UN. Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol. 2006;13:1664–70.CrossRefPubMed

47.

Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol. 2002;26:47–55.CrossRefPubMed

48.

Murakami M, Wada T, Kashiwagi T, Ishida-Yamamoto A, Iizuka H. Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node. J Dermatol. 2007;34:821–8.PubMed

49.

Murali R, Sharma RN, Thompson JF, Stretch JR, Lee CS, McCarthy SW, et al. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). Ann Surg Oncol. 2008;15:302–9.CrossRefPubMed

50.

Urso C, Borgognoni L, Saieva C, Ferrara G, Tinacci G, Begliomini B, et al. Sentinel lymph node biopsy in patients with “atypical Spitz tumors.” A report on 12 cases. Hum Pathol. 2006;37:816–23.CrossRefPubMed

51.

Zuckerman R, Maier JP, Guiney WB Jr, Huntsman WT, Mooney EK. Pediatric melanoma: confirming the diagnosis with sentinel node biopsy. Ann Plast Surg. 2001;46:394–9.CrossRefPubMed

52.

Rodriguez HA, Ackerman LV. Cellular blue nevus. Clinicopathologic study of forty-five cases. Cancer. 1968;21:393–405.CrossRefPubMed

53.

Smith KJ, Barrett TL, Skelton HG III, Morgan AM, Barrett TL, Lupton GP. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol. 1989;13:931–9.PubMedCrossRef

54.

Carlson GW. Age and the incidence of sentinel lymph node metastases in melanoma. Ann Surg Oncol. 2004;11:236–7.CrossRefPubMed

Titel: Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients
verfasst von: Robert Howman-Giles, MD, FRACP, DDU
Helen M. Shaw, PhD
Richard A. Scolyer, MD, FRCPA, FRCPath
Rajmohan Murali, MBBS, FRCPA
James Wilmott, BSc
Stanley W. McCarthy, MB, BS, DCP, FRCPA, FFOP
Roger F. Uren, MD, FRACP, DDU
John F. Thompson, MD, FRACS, FACS
Publikationsdatum: 01.01.2010
Verlag: Springer-Verlag
Erschienen in: Annals of Surgical Oncology / Ausgabe 1/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0657-4

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients